CurrentPremera BluecrossPolicy 2.04.144

Gene Therapy for Inherited Retinal Dystrophy

Clinical evidence, background, regulatory status, and ongoing trials related to gene therapy for inherited retinal dystrophies caused by RPE65 variants; intended for clinicians and payers evaluating medical necessity and coverage.

Policy Summary

PayerPremera Bluecross

PolicyGene Therapy for Inherited Retinal Dystrophy

Policy CodePolicy 2.04.144

Change TypeAnnual review — no material changes

Effective DateApr 1, 2026

Next Review DateApr 1, 2026

Key ActionObtain prior authorization and document confirmed biallelic RPE65 pathogenic variants plus evidence of sufficient viable retinal cells.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

FDA approvedgene therapy available for RPE65-mediated disease

Phase 3 RCT N=31randomized controlled trial demonstrating MLMT improvement

Durability ≥4 yrsfollow-up evidence for voretigene neparvovec

1:130k–1:330kpooled prevalence estimates

since 2018policy history entries beginning

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria — voretigene neparvovec (RPE65)

Initial therapy — voretigene neparvovec

Covered when ALL of the following are met

Genetic confirmation: Confirmed biallelic RPE65 pathogenic variants

Supported by FDA approval and evidence summaries

Viable retinal cells: Documentation of sufficient viable retinal cells for treatment benefit

Referenced in NICE guidance and trial inclusion criteria

Appropriate candidate evaluation: Clinical evaluation demonstrating functional impairment consistent with RPE65-mediated disease (for example, abnormal full-field stimulus threshold [FST] or impaired Multi-Luminance Mobility Test [MLMT]) and absence of contraindications to subretinal AAV therapy

Outcome measures used in pivotal trials include FST and MLMT; adverse events and long-term safety limited

Provider and setting: Administration by experienced retinal surgeons in an appropriate facility with capability for subretinal injection and post-operative monitoring

Gene therapy is delivered by subretinal injection per regulatory documents and clinical trials

Medically necessary indication (historical)

Historical and current policy stance

Medically necessary stance: Voretigene neparvovec (Luxturna) is considered medically necessary for individuals with vision loss due to biallelic RPE65 variant-associated retinal dystrophy who meet policy criteria.

Statement present in policy history since initial policy (11/01/18) and reported unchanged in subsequent annual reviews.

Individuals without confirmed biallelic RPE65 pathogenic variants or without documented evidence of sufficient viable retinal cells for treatment benefit are excluded from coverage for voretigene neparvovec. This reflects eligibility criteria used in clinical trials and regulatory guidance requiring genetic confirmation and demonstration that retinal tissue remains viable to derive clinical benefit.

This medical policy is a guideline for evaluating medical necessity and does not apply to Medicare Advantage. Providers and members should consult the member benefit booklet or contact customer service to confirm plan-specific coverage and benefit limitations.

Use of gene therapies other than the FDA‑approved voretigene neparvovec is considered investigational/experimental due to limited and variable durability and insufficient evidence to determine net health outcome for other constructs evaluated to date.

No additional not medically necessary conditions were added or changed in the most recent review; policy statements were reported unchanged in the latest annual review. As a reminder, coverage determinations remain subject to the member's benefit plan terms and the established policy criteria.

Provider Actions, Prior Authorization & Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for voretigene neparvovec (Luxturna). Follow payer prior authorization procedures and billing guidance for product administration and coding.

Affected codes: HCPCS J3398 (voretigene neparvovec) and relevant CPT codes for subretinal injection (e.g., 67036, 67299)

Denial Risk

Denial Risk if Documentation Is Inadequate

Denial may occur if the clinical documentation does not demonstrate that the patient meets policy criteria — specifically, confirmed biallelic pathogenic or likely pathogenic RPE65 variants, evidence of visual impairment attributable to RPE65‑mediated retinal dystrophy, and sufficient viable retinal cells per FDA guidance and clinical assessments.

Documentation should include genetic testing results confirming biallelic RPE65 pathogenic or likely pathogenic variants.
Document ophthalmologic findings supporting sufficient viable retinal cells (e.g., retinal imaging, visual function testing).

Coding and Billing

Notable codes mentioned in historymixed

J3398	HCPCS code added in 2019 (document notes)
67036	CPT code added (document notes)
67299	CPT unlisted code added (document notes)

Background — Disease, Therapy, and Evidence Summary

Inherited retinal dystrophies are a heterogeneous group of genetic disorders characterized by progressive degeneration of the retina with loss of photoreceptors (rods and cones), commonly presenting with nyctalopia (night blindness) and constriction of peripheral vision. Biallelic pathogenic variants in RPE65 disrupt the visual cycle enzyme RPE65 in retinal pigment epithelium cells, leading to accumulation of toxic precursors, RPE and photoreceptor damage, and eventual vision loss. Gene therapy using adeno-associated virus vectors (notably AAV2) delivers a functional RPE65 gene to RPE cells; the ocular environment’s relative immune privilege and the small, enclosed anatomy of the eye support subretinal gene delivery as performed in clinical trials of voretigene neparvovec.

Definitions and Key Terms

Inherited retinal dystrophies — definition and common clinical presentation

DefinitionA diverse group of disorders with progressive degeneration and dysfunction of the retina, commonly presenting with night blindness (nyctalopia) and loss of peripheral vision.

Pathophysiology summaryProgressive loss of retinal photoreceptors (cones and rods) leading to impaired orientation and navigation in dim light and eventual vision loss; visual acuity may be preserved longer than peripheral vision.

Common clinical presentationNight blindness (nyctalopia), peripheral field constriction, difficulties with mobility and activities of daily living in low-light conditions.

Prognosis noteMost individuals eventually progress to significant vision loss despite variable rates of decline across subtypes.

RPE65-associated retinal dystrophy — definition and pathophysiology

Policy Summary

PayerPremera Bluecross

PolicyGene Therapy for Inherited Retinal Dystrophy

Policy CodePolicy 2.04.144

Change TypeAnnual review — no material changes

Effective DateApr 1, 2026

Next Review DateApr 1, 2026

Key ActionObtain prior authorization and document confirmed biallelic RPE65 pathogenic variants plus evidence of sufficient viable retinal cells.

SourceLink

On This Page

Note

Benefit Verification and Coverage Triggers

Coverage determinations follow this policy and the member’s benefit terms; historical coding or scope exceptions do not guarantee coverage. Member benefit limits, plan‑specific exclusions, or services rendered outside the benefit scope may result in denial.

Verify member benefits and any site‑of‑care or benefit limits prior to authorization.
Services outside of documented benefit scope or lacking prior authorization may be denied.

Documentation Required

Required Documentation

Ensure the medical record includes: confirmatory genetic testing showing biallelic RPE65 pathogenic or likely pathogenic variants, baseline and supporting ophthalmologic assessments demonstrating visual impairment from RPE65‑mediated retinal dystrophy, and documentation of sufficient viable retinal cells consistent with FDA labeling and clinical guidance.

Genetic test report with variant classification (pathogenic/likely pathogenic) and zygosity (biallelic).
Ophthalmology notes, imaging (OCT, fundus exam), and functional testing (FST, MLMT, VA) to document baseline status and viable retinal cells.
Prior authorization submission should include all supporting documentation to reduce risk of denial.

Step Therapy

Therapy Alternatives / Coding Note

There are no approved alternative pharmacologic therapies; step therapy is not applicable. Follow policy and benefit rules for coding and prior authorization updates documented in the policy history.

No step‑therapy requirements applicable.
Review policy history for coding updates (e.g., addition of CPT 67036 and 67299, HCPCS J3398).

Retinal dystrophy caused by biallelic pathogenic variants in RPE65 resulting in loss of the RPE65 isomerase, accumulation of toxic precursors, damage to retinal pigment epithelium (RPE) cells, photoreceptor loss, and eventual blindness.

Genetic requirementDisease associated with biallelic (both alleles) pathogenic variants in the RPE65 gene located at 1p31.3.

Molecular mechanismRPE65 encodes an all-trans retinal isomerase essential for regeneration of 11-cis-retinol in the visual cycle; its absence disrupts the visual cycle.

Clinical consequencesBuild-up of toxic retinoid precursors, RPE cell damage, progressive photoreceptor degeneration, and early-onset severe vision impairment (e.g., RP or LCA subtypes).

AAV (adeno-associated virus) — vector definition and ocular relevance

DefinitionAdeno-associated viruses (AAV) are small, nonenveloped parvoviruses used as viral vectors to deliver therapeutic genes into human cells.

Relevance to ocular gene therapyAAVs (notably serotypes AAV2, AAV5, AAV8) are frequently used in ocular gene therapies because of low immunogenicity, small required vector dose for the eye, and the eye's relative immune privilege.

Biologic propertiesAAVs are dependent on coinfection with helper viruses to replicate and are relatively poorly immunogenic compared with other viral vectors, though immune responses remain a delivery challenge.

Serotypes commonly usedOver 100 AAVs exist; AAV2, AAV5, and AAV8 have been most extensively studied in ocular gene therapies, with recombinant AAV2 most commonly used.

voretigene neparvovec (Luxturna) — product definition and FDA reference

ProductVoretigene neparvovec (Luxturna) is an AAV2-based subretinal gene therapy product for treatment of biallelic RPE65-mediated inherited retinal dystrophy.

Regulatory statusApproved by the U.S. Food and Drug Administration (FDA) on December 19, 2017 (BLA clinical review and advisory materials referenced).

Delivery methodAdministered by subretinal injection to deliver a functional copy of RPE65 to retinal pigment epithelium cells, as used in pivotal clinical trials and regulatory documents.

Supporting evidenceFDA clinical review memorandum and multiple clinical trial publications document safety, efficacy, and follow-up durability data (references and long-term follow-up studies cited).